page_head_bg

Products

liriopesides B*

Description:

CommuniaName: Ophiopogon saponin B
Nomen Anglicum: liriopesides B
CAS No.: 87425-34-1
MolecularWocto: 722.902
Densitas: 1.3 ± 0.1 g / cm3
BoleumPoint: 823.3 ± 65.0 ° C at 760 mmHg
MolecularFormula:C39H62O12
MeltingPoint: n/A
MSDS:N/A
FverberaPoinnium: 451.7 ± 34.3 ° C


Product Detail

Product Tags

Application Of Spicatoside B

Spicatoside B (nolinospiroside f) est saponin steroidalis ab Ophiopogoni japonicis solitaria.Liriopesides B effectus antioxidant et anti-canus.

nomine Spicatoside B

Seres Nomen: Spicatoside B

Nomen anglicum:

β-D-Galactopyranoside, (1β,3β,25S)-3-[(6-deoxy-α-L-mannopyranosyl)oxy]spirost-5-en-1-yl 6-deoxy

Bioactivity Spicatoside B

Descriptio: liliopeside B (nolinospiroside f) est saponin steroidalis ab Ophiopogoni japonicis solitaria.Liriopesides B effectus antioxidant et anti-canus.

Genera cognata:investigationes campi >> alius

Signum iter > > alius > > alius

In Vitro Study: glycoside aristolochia B (nolinopiroside f) crescit SIRT1 actio [1].

.Physicochemical Properties De Spicatoside B
Densitas: 1.3 ± 0.1 g / cm3
Fervens Point: 823.3 ± 65.0 ° C ad 760 mmHg
Formulae hypotheticae: c39h62o12
Molecular pondus: 722.902
Mico Point: 451.7 ± 34.3 ° C
Exacta Missa: 722.424133
PSA:176.76000
LogP:5.42
Vapor Pressura: 0.0 ± 0.6 mmHg in 25° C
Index refractivus: 1.604

English Alias ​​Of Spicatoside B

(1β,3β,25S)-3-[(6-Deoxy-α-L-mannopyranosyl)oxy]spirost-5-en-1-yl 6-deoxy-β-D-galactopyranoside

β-D-Galactopyranoside (1β,3β,25S)-3-[(6-deoxy-α-L-mannopyranosyl)oxy]spirost-5-en-1-yl 6-deoxy-

Liriopesides B

Spirostan, β-D-galactopyranoside deriv.

Liriopeside b

Nolinospiroside F

Product Quality Control

1. Societas nuclearis resonantia magnetica acquisita (Bruker 400MHz) spectrometer, Phase liquidus massa spectrometer (LCMS), gas phase massa spectrometer (GCMs), massa spectrometri (aquae SQD), multiplex analytica latae analytica, chromatographa liquida perficiendi, chromatographa liquida praeparativa, etc. .
2. Societas arctam cooperationem et contactum cum Institutis investigationis scientificis conservat ut Shanghai Institutum ad medicamentorum regimen, biomedicum munus publicum Nanjing suggestum et analysis et centrum Shanghai pharmaceuticae Industry Research Institutum probat.
3. Societas laboratorium tertium factionis probati et certificationis active aget, et CNAs laboratorium accreditationis libellum in fine 2021 obtinebit.


  • Previous:
  • Deinde:

  • Epistulam tuam hic scribe et mitte nobis